药物洗脱支架与冠状动脉旁路移植术治疗左主干病变的死亡率荟萃分析
该荟萃分析纳入5项随机对照试验共4612例左主干冠状动脉疾病患者,比较药物洗脱支架PCI与CABG。加权平均随访67.1个月,两组全因死亡率、心源性死亡、卒中和心肌梗死风险均无显著差异,但PCI组非计划血运重建风险显著增加。
要点
- 左主干病变患者DES-PCI与CABG长期全因死亡率相似(RR 1.03,95%CI 0.81-1.32)。
- 两组心源性死亡、卒中和心肌梗死风险无显著差异。
- DES-PCI组非计划血运重建风险显著高于CABG组(RR 1.73,95%CI 1.49-2.02)。
核心结论
- 左主干冠状动脉疾病患者接受DES-PCI与CABG的长期全因死亡率相似,心源性死亡、卒中和心肌梗死风险亦无显著差异。
- CABG组非计划血运重建发生率低于DES-PCI组。
研究设计与样本
- 系统综述与更新的荟萃分析,纳入5项比较DES-PCI与CABG治疗左主干冠状动脉疾病的随机对照试验。
- 共随机化4612例患者,加权平均随访67.1个月,所有分析均按意向性治疗进行。
主要发现
- 全因死亡率:RR 1.03(95%CI 0.81-1.32),P=0.779。
- 心源性死亡:RR 1.03(95%CI 0.79-1.34),P=0.817。
- 卒中:RR 0.74(95%CI 0.35-1.50),P=0.400。
- 心肌梗死:RR 1.22(95%CI 0.96-1.56),P=0.110。
- 非计划血运重建:RR 1.73(95%CI 1.49-2.02),P<0.001。
临床怎么用
- 对于左主干冠状动脉疾病患者,DES-PCI与CABG在长期死亡风险方面可视为等效选择。
- 选择DES-PCI时应考虑其较高的非计划血运重建风险,需与患者充分沟通。
- 研究结果可为心内科医生、外科医生和患者共同决策提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The optimal method of revascularization for patients with left main coronary artery disease (LMCAD) is controversial. Coronary artery bypass graft surgery (CABG) has traditionally been considered the gold standard therapy, and recent randomized trials comparing CABG with percutaneous coronary intervention (PCI) with drug-eluting stents (DES) have reported conflicting outcomes. We, therefore, performed a systematic review and updated meta-analysis comparing CABG to PCI with DES for the treatment of LMCAD. METHODS AND RESULTS: We systematically identified all randomized trials comparing PCI with DES vs. CABG in patients with LMCAD. The primary efficacy endpoint was all-cause mortality. Secondary endpoints included cardiac death, myocardial infarction (MI), stroke, and unplanned revascularization. All analyses were by intention-to-treat. There were five eligible trials in which 4612 patients were randomized. The weighted mean follow-up duration was 67.1 months. There were no significant differences between PCI and CABG for the risk of all-cause mortality [relative risk (RR) 1.03, 95% confidence interval (CI) 0.81-1.32; P = 0.779] or cardiac death (RR 1.03, 95% CI 0.79-1.34; P = 0.817). There were also no significant differences in the risk of stroke (RR 0.74, 95% CI 0.35-1.50; P = 0.400) or MI (RR 1.22, 95% CI 0.96-1.56; P = 0.110). Percutaneous coronary intervention was associated with an increased risk of unplanned revascularization (RR 1.73, 95% CI 1.49-2.02; P < 0.001). CONCLUSION: The totality of randomized clinical trial evidence demonstrated similar long-term mortality after PCI with DES compared with CABG in patients with LMCAD. Nor were there significant differences in cardiac death, stroke, or MI between PCI and CABG. Unplanned revascularization procedures were less common after CABG compared with PCI. These findings may inform clinical decision-making between cardiologists, surgeons, and patients with LMCAD.
引用
- Ahmad Y, Howard JP, Arnold AD, et al. Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2020. PMID: 32118272. doi:10.1093/eurheartj/ehaa135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。